Free Trial
→ Read now. Do not delete. You’ve been warned. (From Porter & Company) (Ad)tc pixel Free IDXX Stock Alerts

IDEXX Laboratories (IDXX) Stock Forecast & Price Target

IDEXX Laboratories logo
$564.02 +13.04 (+2.37%)
As of 11:31 AM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare

IDEXX Laboratories - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Moderate Buy
Based on 11 Analyst Ratings
Sell
0
Hold
4
Buy
7

Based on 11 Wall Street analysts who have issued ratings for IDEXX Laboratories in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 11 analysts, 4 have given a hold rating, and 7 have given a buy rating for IDXX.

Consensus Price Target

$751.00
33.18% Upside
According to the 11 analysts' twelve-month price targets for IDEXX Laboratories, the average price target is $751.00. The highest price target for IDXX is $830.00, while the lowest price target for IDXX is $640.00. The average price target represents a forecasted upside of 33.18% from the current price of $563.88.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for IDXX and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for IDEXX Laboratories and its competitors.

Sign Up
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

IDXX Analyst Ratings Over Time

TypeCurrent Forecast
5/28/25 to 5/28/26		1 Month Ago
4/28/25 to 4/28/26		3 Months Ago
2/27/25 to 2/27/26		1 Year Ago
5/28/24 to 5/28/25
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
1 Strong Buy rating(s)
Buy
7 Buy rating(s)
7 Buy rating(s)
7 Buy rating(s)
4 Buy rating(s)
Hold
4 Hold rating(s)
4 Hold rating(s)
3 Hold rating(s)
3 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$751.00$760.00$783.33$536.00
Forecasted Upside33.18% Upside33.73% Upside19.28% Upside4.21% Upside
Consensus RatingModerate BuyModerate BuyModerate BuyModerate Buy

IDXX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

IDXX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

IDEXX Laboratories Stock vs. The Competition

TypeIDEXX LaboratoriesMedical CompaniesBroader Market
Consensus Rating Score
2.64
2.30
2.52
Consensus RatingModerate BuyHoldModerate Buy
Predicted Upside33.96% Upside1,701.46% Upside14.97% Upside
News Sentiment Rating
Positive News

See Recent IDXX News
Neutral News
Positive News
Export
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside		Details
5/11/2026
Weiss Ratings logo
Weiss Ratings
Not Rated
 DowngradeHold (C+) ➝ Hold (C)
4/28/2026
UBS Group AG logo
UBS Group
4 of 5 stars
Andrea Alfonso
Andrea Alfonso
Not Rated
Lower TargetNeutral$730.00 ➝ $640.00+12.36%
4/15/2026
Citigroup Inc. logo
Citigroup
4 of 5 stars
Daniel Grosslight
Daniel Grosslight
1 of 5 stars
Initiated CoverageBuy ➝ Neutral$650.00+11.29%
3/31/2026
Stifel Nicolaus logo
Stifel Nicolaus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Jonathan Block
Jonathan Block
Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating
Lower TargetBuy$775.00 ➝ $675.00+21.61%
2/9/2026
Piper Sandler logo
Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
David Westenberg
David Westenberg
Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating
Lower TargetNeutral$775.00 ➝ $750.00+16.35%
2/5/2026
Barclays PLC logo
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Glen Santangelo
Glen Santangelo
Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating
Lower TargetOverweight$850.00 ➝ $800.00+24.43%
2/3/2026
BTIG Research logo
BTIG Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Mark Massaro
Mark Massaro
Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating
Lower TargetBuy$830.00 ➝ $800.00+25.08%
11/4/2025
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Erin Wright
Erin Wright
Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating
Boost TargetOverweight$765.00 ➝ $805.00+11.60%
11/4/2025
Jefferies Financial Group Inc. logo
Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Keith Devas
Keith Devas
Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating
Reiterated RatingBuy$830.00+14.81%
11/4/2025
JPMorgan Chase & Co. logo
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Chris Schott
Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating
Boost TargetOverweight$675.00 ➝ $775.00+8.13%
11/3/2025
Leerink Partners logo
Leerink Partners
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Daniel Clark
Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating
Set Target$785.00+8.58%
2/4/2025
Bank of America Corporation logo
Bank of America
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Michael Ryskin
Michael Ryskin
Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating
Boost TargetNeutral$475.00 ➝ $535.00+14.06%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 11:31 AM ET.


Should I Buy IDEXX Laboratories Stock? IDXX Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, May 22, 2026. Please send any questions or comments about these IDEXX Laboratories pros and cons to contact@marketbeat.com.

IDEXX Laboratories
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in IDEXX Laboratories, Inc.:

  • The current stock price is around $528, which reflects a significant opportunity for potential growth given its historical high of nearly $770.
  • IDEXX Laboratories, Inc. reported a strong quarterly earnings performance, with earnings per share (EPS) of $3.47, exceeding analysts' expectations, indicating robust financial health.
  • The company has demonstrated impressive revenue growth, with a year-over-year increase of 14.3%, suggesting a strong demand for its diagnostic products and services.
  • With a return on equity of 70.87%, IDEXX Laboratories, Inc. shows effective management and profitability, which can be attractive to investors looking for efficient use of equity.
  • The firm has a low debt-to-equity ratio of 0.19, indicating a conservative approach to leverage, which can reduce financial risk for investors.

IDEXX Laboratories
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in IDEXX Laboratories, Inc. for these reasons:

  • The stock has a relatively high price-to-earnings (P/E) ratio of around 40, which may suggest that the stock is overvalued compared to its earnings, potentially limiting upside for new investors.
  • Despite recent growth, the company faces competition in the diagnostic market, which could impact future revenue and market share.
  • The stock has shown volatility with a beta of 1.58, indicating that it may be more sensitive to market fluctuations, which could pose risks for conservative investors.
  • Current financial ratios, such as the quick ratio of 0.82, suggest that the company may have less liquidity to cover short-term obligations, which could be a concern for risk-averse investors.
  • Market capitalization has fluctuated, currently at approximately $41.71 billion, which may indicate uncertainty in investor sentiment and market conditions.

IDXX Forecast - Frequently Asked Questions

According to the research reports of 11 Wall Street equities research analysts, the average twelve-month stock price forecast for IDEXX Laboratories is $751.00, with a high forecast of $830.00 and a low forecast of $640.00.

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IDEXX Laboratories in the last twelve months. There are currently 4 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" IDXX shares.

According to analysts, IDEXX Laboratories's stock has a predicted upside of 33.18% based on their 12-month stock forecasts.

Over the previous 90 days, IDEXX Laboratories's stock had 1 downgrade by analysts.

IDEXX Laboratories has been rated by research analysts at Citigroup, Stifel Nicolaus, UBS Group, and Weiss Ratings in the past 90 days.

Analysts like IDEXX Laboratories more than other "medical" companies. The consensus rating for IDEXX Laboratories is Moderate Buy while the average consensus rating for "medical" companies is Hold. Learn more on how IDXX compares to other companies.

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With IDEXX Laboratories Recommendations


This page (NASDAQ:IDXX) was last updated on 5/28/2026 by MarketBeat.com Staff.
From Our Partners
BNZI Breakout Watch: AI Growth Meets Turnaround Setup!
Banzai International (NASDAQ: BNZI) reported full-year 2025 revenue of $12.2 million, up 169% year-over-year, ...
Huge Alerts | Sponsoredtc pixel
Wall Street’s $3.3B critical mineral darling just got spanked by a $300M junior …
NevGold Corp. (OTCQX: NAUFF) just released drill results showing up to 53.71% antimony - potentially one of th...
i2i Marketing Group, LLC | Sponsoredtc pixel
How to claim a stake in SpaceX before the June 12 IPO
SpaceX is expected to go public on June 12 - and for the first time, everyday investors may have a way in befo...
Brownstone Research | Sponsoredtc pixel
Trump Issues Emergency Order That Supports Elon Musk's Next Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
They're not telling you how bad this could get
Valuations are stretched to levels seen only a handful of times in the last hundred years — yet most retiremen...
Parkview Capital Group | Sponsoredtc pixel
PH: Do THESE 4 things to your bank account now …
In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...
Weiss Ratings | Sponsoredtc pixel
A letter from Shannon Stansberry
Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...
Porter & Company | Sponsoredtc pixel
Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...
After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...
Banyan Hill Publishing | Sponsoredtc pixel